Navigation Links
SEA 2000 Electrophoresis Apparatus

ProductsSEA 2000 Electrophoresis Apparatus
Company Elchrom Scientific AG
Item SEA 2000 Electrophoresis Apparatus
Features 
  • Integrated cooling/heating plate for temperature control during electrophoresis
  • Integrated pump for buffer recirculation
  • Unparalleled homogenous electric field
  • Unparalleled linearity of the electric field
  • Gel compartment: 10.8 x 27.8 cm
  • Buffer volume 1.9 l
  • Optional temperature probe for direct control of the running buffer temperature ( 0.1C)
  • It can be used with Elchrom ready-to-use gels and with self-made agarose gels. In combination with Elchrom ready-to-use gels it provides high reproducibility, high throughput and high resolution.
  • High throughput: simultaneous running of three Mini gels or one Wide Mini gel (up to 400 samples per run)
  • Versatility
  • Unparalleled reproducibility
  • Laminar buffer flow and constant pH even in the vicinity of the electrodes
  • Sharp bands
  • No smiling
Description The SEA 2000 Electrophoresis Apparatus (patented) provides unparalleled reproducibility, speed and convenience for your DNA and RNA electrophoresis.

In combination with Elchrom Scientific AG ready-to-use gels the SEA 2000 covers applications that require a regular submarine plus a vertical or flat bed system.

With the SEA 2000 it is possible to get the best and fastest results in many applications such as PCR checking, RFLP, microsatellites, point mutation analysis (SSCP), etc.

Info 

Related medicine products :

1. CAPILLARYS 2 Capillary Electrophoresis System
2. Paragon CZE 2000 Capillary Electrophoresis System
3. Pore Gradient Lipoprotein Electrophoresis System (PGGE)
4. PSE Electrophoresis Power Supply
5. Elchrom Submerged Gel Electrophoresis Basic System
6. Elchrom Submerged Gel Electrophoresis Premium System
7. Elchrom Submerged Gel Electrophoresis Advanced System
8. Shorter Mini Horizontal Gel Electrophoresis System
9. Mini EZRun Agarose Gel Horizontal Electrophoresis System
10. Gel XL Ultra™ Electrophoresis System
11. Ultra Gel XL Electrophoresis System
Delicate # 4
Curved shafts with fine pointed tips. Smooth handle with dull finish.
Straight tips with delicate serrations. Serrated handle with polished finish.
Delicate lightly curved tips, 1 x 2 mouse style teeth. Serrated handle with polished finish.
Medicine Products:
(Date:12/2/2008)...rsity, The Brigham and Women,s Hospital (Boston), ...as found a new drug with the potential to alleviat.... , Dr Shantha Rajaratnam from Monash Universit...ical Medicine said tasimelteon, a drug which acts ...ghly effective treatment for circadian rhythm slee...
(Date:12/2/2008)...Reminder, the nation,s leading,comprehensive pati...industry,technology today at Javits Center in New...g and distributing video testimonials can be used ...popular platforms such as YouTube, Google,Videos ...ith an effective,business strategy for increasing...
(Date:12/2/2008)...enterprise software and online services veteran is...cribers of Yugma,s instant web conferencing soluti...WEB) December 2, 2008 -- Yugma , the leading web ...collaborate instantly using the Internet, announce...tive Officer. , , ,Vas has more than 20 years of e...
(Date:12/2/2008)...ecific Gamma Imaging (BSGI) has,been proven to be...nosis of,invasive lobular carcinoma (ILC), a diff...lar breast imaging technique that can see lesions ...arly stage cancers. When compared to,mammography,...BSGI has the,greatest sensitivity for detecting I...
Breaking Medicine News(10 mins):Health News:New medication brings hope of jet lag cure 2Health News:Doctors Go Viral: vSling Video Testimonial Tool Offers Doctors Access to New Channels for Acquiring Patients 2Health News:Doctors Go Viral: vSling Video Testimonial Tool Offers Doctors Access to New Channels for Acquiring Patients 3Health News:Yugma Appoints Vas Bhandarkar as Chief Executive Officer 2Health News:Yugma Appoints Vas Bhandarkar as Chief Executive Officer 3Health News:Molecular Breast Imaging Has Greater Sensitivity Over Mammography, Ultrasound and MRI for Invasive Lobular Carcinoma 2
...here is a significant reduction in the case of car...in, both in the case of men and women. In the case... // while in the case of women, the possibilities ...act role of aspirin in bringing down such risks ar...
...GP) was arrested after the death of her patient. ...ted last Friday and was released on bail. // She h...th London. Dr Dhar was arrested and was charged fo...sance and depraving the course of justice. Her pa...
...as very upset and has sent a letter to the acting ...ew von Eschenbach. In his letter he had asked the ...he confusion started when it was reveled that the ...ts in case of tissue transplants. Schumer asked th...
... Beach Resort, located close to Kovalam is expecte...atment of what is called new-age ailments such as ...The unique health care service would be initiated ...Mathew said Monday: "The hospital has been promoti...
Other Medicine News:
(Date:12/1/2008)...ewswire-FirstCall/ -- Genaera Corporation (Nasdaq... has begun in study MSI-1436C-102 (Study 102), the...uemine (MSI-1436) in overweight and obese type 2 d...treatment of type 2 diabetes and obesity which wor...and leptin pathways through the highly selective i...
(Date:12/1/2008)...tCall/ -- Vical Incorporated (Nasdaq: VICL ) ann...ne payment from Merck & Co., Inc. based on Mer...l of an investigational plasmid DNA (pDNA) cancer ... DNA gene delivery technology and encodes human te...he subject of separate license agreement. , ,...
(Date:11/28/2008)...FirstCall/ -- Eli Lilly and Company,(NYSE: LLY ...ion (sNDA) from,the U.S. Food and Drug Administra...he management of chronic pain. Lilly plans to resu...dding data from a recently completed positive stud... The decision does not affect duloxetine,s FD...
(Date:11/26/2008)... , FRANKLIN, Mass., Nov. 26 /PRNewswire-First...SF) announced today that it has received full appr...DA) for its U.S. pivotal trial to study the effect...d associated therapy in the prevention of Contrast...o approved PLC,s request to expand their investiga...
Breaking Medicine Technology:Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 2Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Vigorous activity protects against breast cancer 28359 1Vigorous activity protects against breast cancer 28359 2The Ensign Group Inc Reports Third Quarter 2008 Earnings 3B Reaffirms 2008 Guidance 28357 1The Ensign Group Inc Reports Third Quarter 2008 Earnings 3B Reaffirms 2008 Guidance 28357 2The Ensign Group Inc Reports Third Quarter 2008 Earnings 3B Reaffirms 2008 Guidance 28357 3The Ensign Group Inc Reports Third Quarter 2008 Earnings 3B Reaffirms 2008 Guidance 28357 4The Ensign Group Inc Reports Third Quarter 2008 Earnings 3B Reaffirms 2008 Guidance 28357 5The Ensign Group Inc Reports Third Quarter 2008 Earnings 3B Reaffirms 2008 Guidance 28357 6The Ensign Group Inc Reports Third Quarter 2008 Earnings 3B Reaffirms 2008 Guidance 28357 7The Ensign Group Inc Reports Third Quarter 2008 Earnings 3B Reaffirms 2008 Guidance 28357 8The Ensign Group Inc Reports Third Quarter 2008 Earnings 3B Reaffirms 2008 Guidance 28357 9Heavy Metals Can Taint Wine 28355 1Heavy Metals Can Taint Wine 28355 2Heavy Metals Can Taint Wine 28355 3Schering Plough to Appeal Jury Decision in Missouri Reimbursement Case 28353 1Schering Plough to Appeal Jury Decision in Missouri Reimbursement Case 28353 2
...re/ -- Mersana, a,cancer therapeutics company, ann...ith its lead product candidate, XMT-1001, will,be ...g of the,American Association of Cancer Research (...A. Full text of the abstracts can be,viewed online...http://www.aacr.org/">http://www.AACR.org . , The ...
...risk of cancer,returning after surgery for Kit-pos...atients receiving placebo in this trial will now b... planned for use of Glivec as,adjuvant therapy in ...tumor , * Glivec already approved as effective the...erable Kit-positive GIST , BASEL, Switzerland, Apr...
Other Medicine Technology:Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001,at American Association of Cancer Research Annual Meeting 2Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 2Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 3Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 4Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 5Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 6